Jazz Pharmaceuticals non-GAAP EPS of -$3.88 misses by $1.50, revenue of $1.24B beats by $30M
FROM THE WIRE · SEEKINGALPHA.COM
Jazz Pharmaceuticals Q3 results: EPS missed, revenue beat, and 2026 revenue guidance was raised.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralMixed results: earnings missed but revenue beat and 2026 revenue guidance was raised.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Jazz reported non-GAAP EPS of -$3.88, missing by $1.50.
- 02Revenue was $1.24B, beating by $30M.
- 032026 revenue guidance was raised.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets